Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ONCOTHERANOSTICS

Financiado

Cerrado

Advanced Theranostic Nanomedicines for Oncology. Development of new combinatoria...

Advanced Theranostic Nanomedicines for Oncology. Development of new combinatorial therapies for primary and metastatic Breast Cancer. Despite significant advances in recent years, cancer remains the 2nd cause of death globally. Immunotherapy is an exciting new therapeutic approach that triggers natural immune response against cancer cells. Theranostics is an em... ver más

28/02/2022

CSIC

257K€

Presupuesto del proyecto: 257K€

Líder del proyecto

AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGA... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 2-3 | 552M€

Fecha límite participación Sin fecha límite de participación.

Ver 3 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-02-28

MSCA-IF-2017: Individual Fellowships

I+D

Cerrada hace 7 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

CSIC

257.19K€ | Lider

JOHNS HOPKINS UNIVERSITY

172.13K€ | Participante

Proyectos interesantes

MIRNANO

Nanotechnology

Medical Technol...

244K€ Cerrado

PDC2021-120929-I00

Nanotechnology

Medical Technol...

150K€ Cerrado

NANOTHER

Nanotechnology

Medical Technol...

12M€ Cerrado

CTQ2014-54761-R

Nanotechnology

Medical Technol...

178K€ Cerrado

PRE2019-088029

Nanotechnology

Medical Technol...

98K€ Cerrado

NANO4TARMED

Nanotechnology

Medical Technol...

745K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 46 meses Fecha Inicio: 2018-04-19
Fecha Fin: 2022-02-28

Líder del proyecto

AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGA... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 2-3 | 552M€

Presupuesto del proyecto 257K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Despite significant advances in recent years, cancer remains the 2nd cause of death globally. Immunotherapy is an exciting new therapeutic approach that triggers natural immune response against cancer cells. Theranostics is an emerging therapeutic intervention, that uses dual (or multiple) purpose nanomedine, combining diagnostic and therapeutic effects within a single multifaceted formulation. ONCOTHERANOSTICS proposes the use of a novel theranostic agent to target key tumoral genes by siRNA and monitor the impact of the downregulation non-invasively in vivo. Specific aims include understanding the interplay between choline kinase and tumor escaping natural immune surveillance, and to develop new combinatorial therapies in a model of primary and metastatic triple negative breast cancer. We anticipate that successful completion of the project will result in significant advances in personalized tumor treatments, rendering safer strategies to treat cancer with a dual effect; boosting natural immune response and knocking down one of the main mechanisms of malignancy. Dr. Pacheco is an organic chemist with expertise in MRI who will be trained (outgoing) in nanoparticle synthesis, non-MRI imaging techniques and advanced molecular biology/genetic approaches. Training will be transferred to the host European institution (incoming) by the establishment of a new research line in the emerging field of Theranostics. ONCOTHERANOSTICS seeks to improve our understanding of cancer and how to personalize treatments, fostering the development of nanomedicine targeting specific genes in a way that can be assessed non-invasively. ONCOTHERANOSTICS provides a multidisciplinary environment for cancer treatment, involving multifaceted nanomedicine, multimodal molecular imaging and molecular biology/genetic approaches. The proposal directly addresses the cross cutting priority of personalizing health and care established by H2020, reinforcing European competitiveness in cancer research.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores